文献速递心脑血管急症

根据出血风险决定经皮冠状动脉介入术后双联抗血小板治疗疗程(HOST-BR):一项开放标签、多中心、随机临床试验

Dual antiplatelet therapy after percutaneous coronary intervention according to bleeding risk (HOST-BR): an open-label, multicentre, randomised clinical trial.
PubMed 文献 · Lancet · 2025-10-23
一句话结论高出血风险患者1个月双联抗血小板治疗未达非劣于3个月;非高出血风险患者3个月非劣于12个月且出血更少。

HOST-BR研究在韩国50个心脏中心纳入4897例药物洗脱支架PCI术后患者,按ARC-HBR标准分层。高出血风险层1个月与3个月DAPT比较,净不良临床事件未达非劣效(18.4% vs 14.0%,HR 1.337,95%CI 1.043-1.713)。非高出血风险层3个月与12个月DAPT比较,净不良临床事件非劣(2.9% vs 4.4%,HR 0.657,95%CI 0.455-0.949)且出血更少(7.4% vs 11.7%,HR 0.631,95%CI 0.502-0.793)。高出血风险患者不宜缩短至1个月,非高出血风险患者可考虑3个月DAPT。

要点

  • 高出血风险患者:1个月DAPT较3个月净不良临床事件未达非劣效(18.4% vs 14.0%,HR 1.337,95%CI 1.043-1.713,非劣效P=0.82)。
  • 非高出血风险患者:3个月DAPT净不良临床事件非劣于12个月(2.9% vs 4.4%,HR 0.657,95%CI 0.455-0.949)。
  • 非高出血风险患者:3个月DAPT主要心脑血管事件非劣于12个月(2.2% vs 2.3%,HR 0.984,95%CI 0.622-1.558)。
  • 非高出血风险患者:3个月DAPT出血优于12个月(7.4% vs 11.7%,HR 0.631,95%CI 0.502-0.793,P<0.0001)。
  • 高出血风险患者:1个月DAPT主要心脑血管事件9.8% vs 3个月5.8%,出血13.8% vs 15.8%。

适用人群与场景

  • 年龄≥19岁、接受经皮冠状动脉介入治疗并植入药物洗脱支架的患者,来自韩国50个高容量心脏中心。
  • 按ARC-HBR标准分为高出血风险层(1598例)和非高出血风险层(3299例)。

诊断标准与关键阈值

  • 采用Academic Research Consortium for High Bleeding Risk(ARC-HBR)标准进行出血风险分层。

处置流程与药物剂量

  • 高出血风险层随机接受1个月或3个月DAPT。
  • 非高出血风险层随机接受3个月或12个月DAPT。

研究设计与关键结果

  • 开放标签、多中心、随机临床试验,纳入4897例患者(高出血风险层1598例,非高出血风险层3299例),随机时间为2020年7月24日至2023年9月25日。
  • 高出血风险层:1个月DAPT组净不良临床事件144/798(18.4%)vs 3个月组110/800(14.0%),HR 1.337(95%CI 1.043-1.713),非劣效P=0.82(未达非劣效)。
  • 高出血风险层:1个月组主要心脑血管事件74例(9.8%)vs 3个月组44例(5.8%);出血105例(13.8%)vs 122例(15.8%)。
  • 非高出血风险层:3个月DAPT组净不良临床事件47/1649(2.9%)vs 12个月组72/1650(4.4%),HR 0.657(95%CI 0.455-0.949),非劣效P<0.0001。
  • 非高出血风险层:3个月组主要心脑血管事件36例(2.2%)vs 12个月组37例(2.3%),HR 0.984(95%CI 0.622-1.558),非劣效P=0.0082;出血120例(7.4%)vs 190例(11.7%),HR 0.631(95%CI 0.502-0.793),P<0.0001。

证据类型、等级与局限

  • 证据类型:开放标签、多中心、随机临床试验。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 高出血风险患者PCI术后DAPT缩短至1个月未达非劣效,1个月组净不良临床事件和主要心脑血管事件数值均高于3个月组。
  • 非高出血风险患者PCI术后3个月DAPT在净不良临床事件和主要心脑血管事件上非劣于12个月,且出血更少,支持缩短DAPT疗程。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: The optimal duration of dual antiplatelet therapy (DAPT) after coronary stenting according to bleeding risk is not well established. We aimed to evaluate the optimal duration of DAPT after coronary stenting according to bleeding risk.

METHODS: In this open-label, multicentre, randomised clinical trial, patients aged 19 years and older who received percutaneous coronary intervention with a drug-eluting stent at 50 high-volume cardiology centres in South Korea were stratified into high bleeding risk (HBR) or non-HBR strata, according to Academic Research Consortium for High Bleeding Risk criteria. Patients in the HBR stratum were randomly assigned (1:1) to 1-month or 3-month DAPT, and those in the non-HBR stratum were randomly assigned (1:1) to 3-month or 12-month DAPT. The three coprimary endpoints were net adverse clinical events (all-cause death, myocardial infarction, stent thrombosis, stroke, or major bleeding), major adverse cardiac or cerebral events (cardiovascular death, myocardial infarction, definite or probable stent thrombosis, or ischaemic stroke), and any actionable non-surgical bleeding at 1 year after randomisation. Primary endpoints were assessed in hierarchical order in the intention-to-treat population. This study is registered with cris.nih.go.kr, KCT0005356, and ClinicalTrials.gov, NCT05631769, and is complete.

FINDINGS: From July 24, 2020, to Sept 25, 2023, 4897 patients were enrolled (1598 in the HBR stratum and 3299 in the non-HBR stratum). In the HBR stratum, 1-month compared with 3-month DAPT did not reach non-inferiority for net adverse clinical events (144 [18·4%] of 798 vs 110 [14·0%] of 800 patients; hazard ratio [HR] 1·337 [95% CI 1·043-1·713]; p=0·82 for non-inferiority). Major adverse cardiac or cerebral events occurred in 74 (9·8%) patients in the 1-month DAPT group and 44 (5·8%) in the 3-month group; bleeding occurred in 105 (13·8%) patients in the 1-month group and 122 (15·8%) in the 3-month group. In the non-HBR stratum, 3-month was non-inferior to 12-month DAPT regarding net adverse clinical events (47 [2·9%] of 1649 vs 72 [4·4%] of 1650 patients; HR 0·657 [0·455-0·949]; p<0·0001 for non-inferiority) and major adverse cardiac or cerebral events (36 [2·2%] vs 37 [2·3%]; HR 0·984 [0·622-1·558]; p=0·0082 for non-inferiority), and superior for bleeding (120 [7·4%] vs 190 [11·7%]; HR 0·631 [0·502-0·793]; p<0·0001).

INTERPRETATION: In east Asian patients with HBR, 1-month DAPT did not reach non-inferiority to 3-month DAPT for net adverse clinical events. In patients without HBR, 3-month DAPT was non-inferior to 12-month DAPT regarding net adverse clinical events and major adverse cardiac or cerebral events, and superior for bleeding.

FUNDING: Medtronic and Abbott.

来源:Lancet,查看原文。版权归原作者所有。

参考来源

  1. Kang J, Park KW, Han JK, et al. Dual antiplatelet therapy after percutaneous coronary intervention according to bleeding risk (HOST-BR): an open-label, multicentre, randomised clinical trial. Lancet. 2025. PMID: 41631724. doi:10.1016/S0140-6736(25)01571-5

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。